Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy.

摘要: Treatment with human recombinant interleukin-2 (rIL-2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of effectiveness and excessive toxicity often associated use. The mechanisms responsible for immune-mediated tumor regression those limiting have not yet been sorted out. Thus, this review critically addresses what has done past to understand biologically practically important question discusses future strategies enhance understanding interesting model rejection. In particular, first aim discuss known about mechanism(s) rejection; second relationship between induced rIL-2 treatment effectiveness; third summarize novel insights into possible mechanism activity vivo using high-throughput aimed at global assessment real-time events therapy humans. This information will only lead a better biological agent clinical practice but it may also provide how tissue rejection occurs.